Breast Cancer Research and Treatment

, Volume 70, Issue 1, pp 1–10

Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline

  • G. Pezzella
  • R. Moslinger-Gehmayr
  • A. Contu
Article

Abstract

In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability. Prompt diagnosis and effective treatment is, therefore, essential. Several small studies have established the efficacy of tricyclic antidepressants (TCAs) in this setting, and the selective serotonin reuptake inhibitors (SSRIs) would appear to be an alternative therapeutic option because of their established efficacy and better tolerability profile. This was a multicenter, double-blind, parallel-group study in which 179 women with breast cancer were randomized to treatment with either the SSRI paroxetine (20–40mg/day), or the TCA, amitriptyline (75–150mg/day). After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale. Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint; a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale. A steady improvement in quality of life was also observed in both groups. There were no clinically significant differences between the groups. In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy. Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%). This study has demonstrated that paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.

breast cancer depression selective serotonin reuptake inhibitor (SSRI) tricyclic antidepressant (TCA) amitriptyline paroxetine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Massie MJ, Holland JC: Depression and the cancer patient. J Clin Psychiatry 51: 12-17, 1990Google Scholar
  2. 2.
    Aapro M, Cull A: Depression in breast cancer patients: the need for treatment. Annals Oncol 10: 1-10, 1998Google Scholar
  3. 3.
    Black RJ, Bray F, Ferlay J, Parkin DM: Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075-1107, 1997Google Scholar
  4. 4.
    Katon W, Kleinman A, Rosen G: Depression and somatization: a review. Am J Med 72: 127-135, 1982Google Scholar
  5. 5.
    Wells KB, Golding JM, Burnham MA: Psychiatric disorder and limitations in physical functioning in a sample of Los Angeles general population. Am J Psychiatry 145: 712-717, 1998Google Scholar
  6. 6.
    Wells KB, Golding JM, Burnam MA: Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry 145: 976-981, 1988Google Scholar
  7. 7.
    Katon W, Sullivan MD: Depression and chronic medical illness. J Clin Psychiatry 51: 3-11, 1990Google Scholar
  8. 8.
    Bottomley A: Depression in cancer patients: a literature review. Eur J Cancer Care (Engl) 7: 181-191, 1998Google Scholar
  9. 9.
    Newport DJ, Nemeroff CB: Assessment and treatment of depression in the cancer patient. J Psychosom Res 45: 215-237, 1998Google Scholar
  10. 10.
    Haig RA: Management of depression in patients with advanced cancer. Med J Aust 156: 499-503, 1992Google Scholar
  11. 11.
    Ayres A, Hoon PW, Franzoni JB, Matheny KB, Cotanch PH, Takayanagi S: Influence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer. J Psychosom Res 38: 393-402, 1994Google Scholar
  12. 12.
    Costa D, Mogos I, Toma T: Efficacy and safety of Mianserin in the treatment of depression in women with cancer. Acta Psychiatr Scand 72: 499-503, 1985Google Scholar
  13. 13.
    Greer S: Cancer and the mind. Br J Psychiatry 143: 535-543, 1983Google Scholar
  14. 14.
    Pettingale KW, Morris T, Greer S, Haybittle JL: Mental attitudes to cancer: an additional prognostic factor. Lancet I: 750, 1985Google Scholar
  15. 15.
    Purohit DR, Navalakha PL, Modi RS, Eshpumiyani R: The role of antidepressants in hospitalised cancer patients. J Assoc Physicians India 26: 245-248, 1978Google Scholar
  16. 16.
    Rifkin A, Reardon G, Siris S, Karagji B, Kim YS, Hackstaff L, Endicott N: Trimipramine in physical illness with depression. J Clin Psychiat 46: 4-8, 1985Google Scholar
  17. 17.
    Schwartz JA, Speed N, Beresford TP: Antidepressants in the medically ill: prediction of benefits. Int J Psychiatry Med 19: 363-369, 1989Google Scholar
  18. 18.
    van Heerigen K, Zickov M: Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 169: 440-443, 1996Google Scholar
  19. 19.
    Popkin MK, Callies AL, Mackenzie TB: The outcome of antidepressant use in the medically ill. Arch Gen Psychiat 42: 1160-1163, 1985Google Scholar
  20. 20.
    Maguire P, Hopwood P, Tarrier N, Howell T: Treatment of depression in cancer patients. Acta Psychiatrica Scandinavia 72: 81-84, 1985Google Scholar
  21. 21.
    Eija K, Tiina T, Pertti NJ: Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 64: 293-302, 1996Google Scholar
  22. 22.
    Feighner JP, Boyer WF: Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 80: 125-129, 1989Google Scholar
  23. 23.
    Hutchinson DR, Tong S, Moon CAL, Vince M, Clarke A: A double-blind study in general practice to compare the efficacy and tolerability of paroxetine and amitriptyline in depressed elderly patients. Br J Clin Res 2: 43-57, 1991Google Scholar
  24. 24.
    Pelicier Y, Schaeffer P: Multicenter double-blind study comparing the efficacy and tolerance of paroxetine and clomipramine in reactive depression in the elderly patient. Encephale 19: 257-261, 1993Google Scholar
  25. 25.
    Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH: A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. J Clin Psychiatry 58: 112-118, 1997Google Scholar
  26. 26.
    Shillinford JS: A double-blind comparison of paroxetine and dothiep in on efficacy and tolerability in depressed community patients. Presented at 17th CINP Congress, Kyoto, 1990Google Scholar
  27. 27.
    Moon CAL, Khong TK, Lee P, Vince M: A double-blind comparison of paroxetine and lofepramine in depressed community patients. Presented at the 18th CINP Congress, Nice, 1992Google Scholar
  28. 28.
    Boyer WF, Blumhardt CL: The safety profile of paroxetine. J Clin Psychiatry 53: 61-66, 1991Google Scholar
  29. 29.
    Robbe HWJ, O'Hanlon JF: Acute and subchronic effects of paroxetine 20 and 40mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur J Neuropsychopharmcol 5: 35-42, 1995Google Scholar
  30. 30.
    Hindmarch I, Harrison C: The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity relate to car driving. Human Psychopharmacol 3: 13-20, 1988Google Scholar
  31. 31.
    Hindmarch I: Behavioural toxicity of antianxiety and antidepressant agents. Hum Psychopharmacol 14: 137-141, 1999Google Scholar
  32. 32.
    Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 322-329, 1979Google Scholar
  33. 33.
    Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, Derde MP, Beauduin M, Piccart M: Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotheropy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11: 1384-1390, 1993Google Scholar
  34. 34.
    Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, Saltel P, Piollet I, Gauvain-Piquard A, Trichard C, Cordier B, Fresco R, Guillibert E, Sechter D, Orth JP, Bouhassira M, Mestess P, Blin P: The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 94: 205-210, 1996Google Scholar
  35. 35.
    Hooper CL, Bakish D An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci 25(2): 178-184, 2000Google Scholar
  36. 36.
    Stark P, Hardison CD: A review of multicenter controlled studies of fluoxetine versus imipramine and placebo in major depressive disorders. J Clin Psychiatry 46: 53-58, 1985Google Scholar
  37. 37.
    Fawcett J, Zajecka JM, Kravitz HM, Edwards J, Jeffries H, Scorza E: Fluoxetine versus amitriptyline in adult outpatients with major depression. Curr Ther Res 45: 821-832, 1989Google Scholar
  38. 38.
    Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, Shrivastava RK: A comparison of paroxetine, imipramine, and placebo in depressed out-patients. Br J Psychiatry 159: 394-398, 1991Google Scholar
  39. 39.
    Link C, Dunbar GC: An overview of studies comparing the ef-ficacy, safety and tolerability of paroxetine and clomipramine. Nord J Psychiatry 27: 17-22, 1992Google Scholar
  40. 40.
    Stott PC, Blagden MD, Aitken CA: Depression and associated anxiety in primary care: a double-blind comparison of paroxetine and amitriptyline. Eur Neuropsychopharmacol 3: 324-325, 1993Google Scholar
  41. 41.
    Cooper GL: The safety of fluoxetine-an update. Br J Psychiatry 1988; 153: 77-86, 1988Google Scholar
  42. 42.
    Jenner PN: Paroxetine: an overview of dosage, tolerability and safety. Int Clin Psychopharmacol 6: 69-80, 1992Google Scholar
  43. 43.
    Tylee A, Kumar R: Depression comorbid with medical illness-treatment with paroxetine. Poster presentation, 11th ECNP, Paris, France, 1998Google Scholar
  44. 44.
    Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG: A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 7: 291-300, 1998Google Scholar
  45. 45.
    Ballenger J, Davidson JRT, Lecrubier Y, Nutt DJ (International Consensus Group on Depression and Anxiety), Goldberg D, Magruder KM, Schulberg HC, Tylee A, Wittchen H-U: Consensus Statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 60: 54-61, 1999Google Scholar
  46. 46.
    O'Hanlon JF: Antidepressant therapy and behavioural competence. Br J Clin Pract 50: 381-385, 1996Google Scholar
  47. 47.
    Theesen KA, Marsh WR: Relief of diabetic neuropathy with fluoxetine. DICP 23: 572-574, 1989Google Scholar
  48. 48.
    Foster CA, Bafaloukos J: Paroxetine in the treatment of chronic daily headache. Headache 34: 587-589, 1994Google Scholar
  49. 49.
    Langemark M, Olesem J: Sulpiride and paroxetine in the treatment of chronic tension-like headache. An explanatory double-blind trial. Headache 34: 20-24, 1994Google Scholar
  50. 50.
    Gunasekara NS, Noble S, Benfield P: Paroxetine: An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 55: 85-120, 1998Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • G. Pezzella
    • 1
  • R. Moslinger-Gehmayr
    • 2
  • A. Contu
    • 3
  1. 1.Azienda Ospedaliera Santissima AnnunziataUnita Operativa di Oncologia MedicaTarantoItaly
  2. 2.Universitätsklinik für FrauenheilkundeViennaAustria
  3. 3.Ospedale Civile di Sassari, Divisione di OncologiaSassariItaly

Personalised recommendations